CN109646562A - A kind of slug compound preparation and preparation method thereof for preventing and treating COPD - Google Patents
A kind of slug compound preparation and preparation method thereof for preventing and treating COPD Download PDFInfo
- Publication number
- CN109646562A CN109646562A CN201910077918.9A CN201910077918A CN109646562A CN 109646562 A CN109646562 A CN 109646562A CN 201910077918 A CN201910077918 A CN 201910077918A CN 109646562 A CN109646562 A CN 109646562A
- Authority
- CN
- China
- Prior art keywords
- extract
- slug
- parts
- copd
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 150000001875 compounds Chemical class 0.000 title claims abstract description 15
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 18
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 18
- 235000017443 Hedysarum boreale Nutrition 0.000 claims abstract description 15
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims abstract description 15
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims abstract description 15
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 14
- 235000009566 rice Nutrition 0.000 claims abstract description 14
- 241001547125 Fritillaria thunbergii Species 0.000 claims abstract description 5
- 230000002265 prevention Effects 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 14
- 241000209094 Oryza Species 0.000 claims description 13
- 238000001914 filtration Methods 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 239000006072 paste Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 235000019441 ethanol Nutrition 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 4
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 4
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 4
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims description 3
- 238000007598 dipping method Methods 0.000 claims description 3
- 238000005538 encapsulation Methods 0.000 claims description 3
- 239000001685 glycyrrhizic acid Substances 0.000 claims description 3
- 235000011477 liquorice Nutrition 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 239000002893 slag Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 238000010257 thawing Methods 0.000 claims description 3
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 3
- 230000000903 blocking effect Effects 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract description 33
- 230000000694 effects Effects 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 4
- 230000034994 death Effects 0.000 abstract description 3
- 230000008859 change Effects 0.000 abstract description 2
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 240000007594 Oryza sativa Species 0.000 abstract 1
- 206010011224 Cough Diseases 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 13
- 230000002685 pulmonary effect Effects 0.000 description 13
- 206010036790 Productive cough Diseases 0.000 description 7
- 230000006870 function Effects 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 208000000059 Dyspnea Diseases 0.000 description 5
- 206010013975 Dyspnoeas Diseases 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 208000000884 Airway Obstruction Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 3
- 210000003123 bronchiole Anatomy 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 208000002815 pulmonary hypertension Diseases 0.000 description 3
- 208000013220 shortness of breath Diseases 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 206010047924 Wheezing Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009798 acute exacerbation Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- 229960004399 carbocisteine Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000013116 chronic cough Diseases 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000004493 neutrocyte Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 description 1
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000012219 Autonomic Nervous System disease Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010009126 Chronic respiratory failure Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 206010010970 Cor pulmonale chronic Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000605372 Fritillaria Species 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020591 Hypercapnia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 1
- UZIQYAYUUNMDMU-UHFFFAOYSA-N N.[Br+] Chemical compound N.[Br+] UZIQYAYUUNMDMU-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229960000985 ambroxol hydrochloride Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 208000026636 chronic pulmonary heart disease Diseases 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006828 endometrial hyperplasia Diseases 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 229940040493 myrtol Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004088 pulmonary circulation Effects 0.000 description 1
- 238000009613 pulmonary function test Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 230000036301 sexual development Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention prevents and treats COPD using slug extract and fritillaria thunbergii and extract of licorice root combination collocation, and effect is good, and treating both manifestation and root cause of disease, has filled up the blank of single medicine prevention and treatment COPD；Nontoxic, no contraindication is suitable for COPD people at highest risk；Medicine source is abundant, and can industrialization cultivation, change harmful to treasure.Since COPD disease incidence is high, disability rate is high, the death rate is high and without specific treatment method, technical solution of the present invention, the huge market demand, and Social benefit and economic benefit is good.A kind of slug compound preparation for preventing and treating COPD, feature includes following raw material: 3-18 parts of slug extract, 1.5-9 parts of wash rice Bulbus Fritillariae Cirrhosae extract, 0.5-3 parts of extract of licorice root.
Description
Technical field
The present invention relates to a kind of health care product, especially a kind of slug compound preparation and preparation method thereof for preventing and treating COPD.
Background technique
COPD is discussed surely
Chronic Obstructive Pulmonary Disease (COPD) is a kind of disease that can be prevented and treated with flow limitation feature.Its gas
Stream be limited it is not fully reversible, in sexual development is carried out, with lungs to the abnormal inflammatory of sucking tobacco smoke etc. pernicious gases or particle
React related.COPD mainly involves lungs, but can also cause the ill effect of whole body (or outside lung).Pulmonary function test is to clear
It is significant with the presence or absence of flow limitation.After sucking bronchodilators, if first second forced expiratory volume occupies
The percentage (FEV1/FVC%) < 70% of power lung capacity, then show that there are not fully reversible flow limitations.
The pathogenesis of COPD
The chronic stimulations object such as tobacco smoke acts on lung, and lung is made abnormal inflammatory reaction occur.It is real that COPD can be involved air flue, lung
Matter and Pulmonary Vascular show as the chronic inflammatory reaction for occurring based on neutrophil leucocyte, macrophage, lymphocytic infiltration.This
A little cell release inflammatory mediators and air flue and the Constituent cell of pulmonary parenchyma interact, and then promote T lymphocyte (especially CD
+ 8) assemble with neutrophil leucocyte and eosinophil in lung tissue, it is release leukotriene B4 (LTB4), interleukin 8 (IL-8), swollen
A variety of media such as tumor necrosis factor α (TNF-α), cause the destruction of lung structure.Oxidation, anti-oxidant unbalance and protease, anti-albumen
Enzyme is unbalance and function disorder of autonomic nervous system, and cholinergic nerve tension increases etc., and that COPD lung inflammation is further aggravated is gentle
Stream is limited.And hereditary susceptibility plays a role in morbidity.
The pathologic, physiologic of COPD
It includes that mucous secretion caused by air flue and pulmonary parenchyma chronic inflammation increases, fibre function loses that the Pathological Physiology of COPD, which changes,
Tune, flow limitation, excessively inflation, gas exchanges exception, pulmonary hypertension and pulmonary heart disease and systemic adverse reactions.Mucous secretion increases
Mostly lead to chronic cough and expectoration with fibre function imbalance.Small airway inflammation, fibrosis and lumen secretion increase cause FEV1,
FEV1/FVC is reduced.Occur after small airway obstruction gas fall into close, can lead to alveolar and excessively inflate.Excessively inflation makes function residual capacity
Increase and aspirated volume declines, causes expiratory dyspnea and locomitivity limited.It is now recognized that excessively inflation is in disease early stage
The main reason for occurring, being shortness of breath after causing activity.With progression of disease, airway obstruction, the destruction of pulmonary parenchyma and pulmonary vascular bed
It aggravates, declines pulmonary ventilation and gas exchange capacity further, lead to hypoxemia and hypercapnia.Long-term chronic anoxic can
Pulmonary Vascular is caused to shrink extensively and pulmonary hypertension.Pulmonary Vascular endometrial hyperplasia, occurs fibrosis and occlusion causes pulmonary circulation to reconstruct.
There is pulmonary hypertension in the COPD later period, and then chronic pulmonary heart disease and right heart insufficiency occurs.
The pathological anatomy of COPD
COPD involves central airway, peripheral airway, pulmonary parenchyma and Pulmonary Vascular.(trachea-bronchial epithelial cell and internal diameter are greater than central airway
The bronchiole of 2-4mm) surface epithelium inflammatory cell infiltration, mucous secretion hylperadenosis and goblet cell, which increase, increases mucous secretion
Add.In peripheral airway (bronchium and bronchiole that internal diameter is less than 2mm), chronic inflammation causes airway walls to damage and repair
Process repeated.Airway walls structural remodeling occurs in repair process, collagen content increases and cicatricial tissue is formed, these changes
Airway constriction is caused, stationarity airway obstruction is caused.The involvement of COPD pulmonary parenchyma shows as centrilobular type pulmonary emphysema, involves breathing
, there is lumen distention and destruction in property bronchiole.Diseased region often betides the upper area of lung when the state of an illness is lighter, when the state of an illness into
Zhan Hou can be involved full lung, with the destruction of pulmonary capillaries bed: show as intimal thickening, proliferation of smooth muscle and vessel wall inflammation
Cellular infiltration.
The clinical symptoms of COPD
(1), chronic cough: being often onset symptoms.It just coughs for discontinuity, morning is heavier, sooner or later or can have cough all day later
It coughs, nocturnal cough is not often significant.Small number of patients is without cough symptom, but lung function shows obvious flow limitation.
(2), expectoration: a small amount of mucous sputum of cough, early morning are more.Amount of expectoration increases when concurrent infection, can there is purulent sputum.Minority is suffered from
Person's cough is not with expectoration.
(3), shortness of breath or expiratory dyspnea: being the typical performance of COPD.Early stage only occur after activity, after gradually aggravate, sternly
Weight when daily routines even rest when also feel shortness of breath.
(4), wheeze: some patientss, especially severe patient may occur in which wheezing symptoms.
(5), systemic symptoms: weight loss, appetite stimulator, periphery muscular atrophy and dysfunction, mental depression and
(or) anxiety etc..Finally development generates chronic respiratory failure, pulmonary encephalopathy and death.
Currently, COPD, currently without special treatment method, conventional method is as follows:
(1) bronchodilators are the critical treatment drugs for controlling COPD symptom:
β 2 receptor agonist: short-acting β 2 receptor agonist mainly has salbutamol, Terbutaline etc. to quantify atomized inhalation, number
It works in minute；Long-effect β_2 reactant excitomotor agent mainly has salmeterol, Formoterol etc..
Anticholinergic agent: short-acting anticholinergic agent mainly has Ipratropium Bromide to quantify atomized inhalation, and long-acting anticholinergic agent mainly has thiophene
Hold in the palm bromine ammonium.
Methyl xanthine class drug: including short-acting and long-acting dosage form.Short-acting dosage form such as aminophylline, long-acting dosage form are such as sustained tea
Alkali.
(2) glucocorticoid: long-term rule inhaled is suitable for severe and pole severe and repeatedly acute exacerbation
Patient can reduce acute exacerbation number, increase exercise tolerance, quality of making the life better, but cannot prevent the downward trend of FEV1.Connection
Inhaled and Long-effect β_2 reactant excitomotor agent are closed, curative effect is better than single formulation.Long-term Oral, intramuscular injection or vein are not recommended
Using glucocorticoid treatment.
(3) other drugs.
Expectorant: there are ambroxol hydrochloride, acetylcysteine, carbocisteine, myrtol etc..
Antioxidant: such as carbocisteine, N-acetylcystein.
These above-mentioned Drug combinations can just receive certain effect, have no that a kind of drug can prevent and treat the report of COPD at present
Road.
Summary of the invention
The purpose of the present invention is to solve shortcomings in the prior art, and provide one kind and have no toxic side effect, use
The slug compound preparation and preparation method thereof of convenient, applied widely, quick prevention and treatment COPD.
The technical scheme is that a kind of slug compound preparation for preventing and treating COPD, feature includes that following parts by weight are former
Material:
3-18 parts of slug extract, 1.5-9 parts of wash rice Bulbus Fritillariae Cirrhosae extract, 0.5-3 parts of extract of licorice root.
A kind of preparation method of slug compound preparation that preventing and treating COPD, it is characterized in that by following processing step:
1, prepare slug extract: slug after taking fresh slug or thawing sets in pure water and is homogenized, be centrifuged in 4 DEG C of environment, abandons
Slag operates repeatedly, until liquid-to-solid ratio is 2:1, then in 4 DEG C of environment, after standing 24 hours, filters out fat and freezes blocking
Shape, then vacuum freeze drying is carried out, the loose block powder obtained after dry；
2, it prepares wash rice Bulbus Fritillariae Cirrhosae extract: taking fritillaria thunbergii, be ground into coarse powder, with 70% ethanol as solvent, dipping is seeped after 18 hours
It filters, collects liquid of just filtering, another device saves, and continues diacolation, and soluble component of waiting is filtered out completely, and liquid of filtering is added and is concentrated at 60 DEG C or less
Paste is added and is just filtered liquid, is mixed, and 70% ethyl alcohol is added to dilute, and is stood, filtration to get；
3, prepare extract of licorice root: extracting liquorice moisturizes, and slice adds water to cook three times, 2 hours every time, collecting decoction, places 12-16
Hour makes to precipitate, and takes out supernatant until being concentrated into paste, takes out in right amount, and measurement glycyrrhizic acid content, adjusting makes to meet regulation,
Re-dry, and wear into fine powder to get；
4, it mixes, pack: 1 part of 6 parts of slug extract, 3 parts of wash rice Bulbus Fritillariae Cirrhosae extract, extract of licorice root mixing being crushed, 20 meshes is crossed, obtains
Lark powder, package encapsulation, low temperature drying are at product.
Further embodiment is: following proportion is used in mixing, packaging step:
6 parts of slug extract, 3 parts of wash rice Bulbus Fritillariae Cirrhosae extract, 1 part of extract of licorice root.
Further embodiment is: mixing, after packaging step again by the product after low temperature drying be further processed into tablet,
Paste, spray or suppository.
The effect that each raw material in technical solution of the present invention generate:
Slug: having clearing heat and detoxicating, promoting blood circulation Eradicates block up, the functions such as resolving hard lump, be usually used in treating cough, asthma, phlegm toot, abscess of throat；
Wash rice fritillaria: clearing heat and eliminating phlegm, powder detoxifcation.Control cough due to wind-heat evil, lung carbuncle larynx numbness, scrofula, sore swollen toxin.It is flat to reinforce slug cough-relieving
Asthma effect；
Radix Glycyrrhizae: contain flavonoids and triterpenes class compound in Radix Glycyrrhizae, there is antibacterial, antiviral antitumor action.It is i.e. clearing heat and detoxicating
Effect；Radix Glycyrrhizae it is warm-natured and, the glycyrrhizin contained can be removed intracorporal damp and hot, and the enoxolone in Radix Glycyrrhizae can promote
Air way mucus secretion has the function of relieving cough and moistening lung resolving sputum.
The invention adopts the above technical scheme, using slug extract and fritillaria thunbergii and extract of licorice root combination collocation, prevention and treatment
COPD, effect is good, and treating both manifestation and root cause of disease, has filled up the blank of single medicine prevention and treatment COPD；Nontoxic, no contraindication is suitable for the high-risk people of COPD
Group；Medicine source is abundant, and can industrialization cultivation, change harmful to treasure.Since COPD disease incidence is high, disability rate height, the death rate are high and without spy
Effect treatment method, technical solution of the present invention, the huge market demand, Social benefit and economic benefit are good.
Specific embodiment
Embodiment
A kind of slug compound preparation for preventing and treating COPD, feature includes following raw material:
6 parts of slug extract, 3 parts of wash rice Bulbus Fritillariae Cirrhosae extract, 1 part of extract of licorice root.
A kind of preparation method of slug compound preparation that preventing and treating COPD, it is characterized in that by following processing step:
1, prepare slug extract: slug after taking fresh slug or thawing sets in pure water and is homogenized, be centrifuged in 4 DEG C of environment, abandons
Slag operates 3 times repeatedly, until liquid-to-solid ratio is 2:1, then in 4 DEG C of environment, after standing 24 hours, filters out fat and is frozen into
The bulk of 1CM thickness, then vacuum freeze drying is carried out, the loose block powder obtained after dry；
2, it prepares wash rice Bulbus Fritillariae Cirrhosae extract: taking fritillaria thunbergii, be ground into coarse powder, with 70% ethanol as solvent, dipping is seeped after 18 hours
It filters, collects liquid of just filtering, another device saves, and continues diacolation, and soluble component of waiting is filtered out completely, and liquid of filtering is added and is concentrated at 60 DEG C or less
Paste is added and is just filtered liquid, is mixed, and 70% ethyl alcohol is added to dilute, and is stood, filtration to get；
3, prepare extract of licorice root: extracting liquorice moisturizes, and slice adds water to cook three times, 2 hours every time, collecting decoction, places 12-16
Hour makes to precipitate, and takes out supernatant until being concentrated into paste, takes out in right amount, and measurement glycyrrhizic acid content, adjusting makes to meet regulation,
Re-dry, and wear into fine powder to get；
4, it mixes, pack: 1 part of 6 parts of slug extract, 3 parts of wash rice Bulbus Fritillariae Cirrhosae extract, extract of licorice root mixing being crushed, 20 meshes is crossed, obtains
Lark powder, package encapsulation, low temperature drying are at product.
Further embodiment is: mixing, after packaging step again by the product after low temperature drying be further processed into tablet,
Paste, spray or suppository.
Claims (5)
1. a kind of slug compound preparation for preventing and treating COPD, feature includes following raw material:
3-18 parts of slug extract, 1.5-9 parts of wash rice Bulbus Fritillariae Cirrhosae extract, 0.5-3 parts of extract of licorice root.
2. a kind of slug compound preparation for preventing and treating COPD as described in claim 1, feature includes following raw material:
6 parts of slug extract, 3 parts of wash rice Bulbus Fritillariae Cirrhosae extract, 1 part of extract of licorice root.
3. a kind of preparation method for the slug compound preparation for preventing and treating COPD, it is characterized in that by following processing step:
(1), prepare slug extract: slug after taking fresh slug or thawing sets in pure water and is homogenized, be centrifuged in 4 DEG C of environment, abandons
Slag operates repeatedly, until liquid-to-solid ratio is 2:1, then in 4 DEG C of environment, after standing 24 hours, filters out fat and freezes blocking
Shape, then vacuum freeze drying is carried out, the loose block powder obtained after dry；
(2), it prepares wash rice Bulbus Fritillariae Cirrhosae extract: taking fritillaria thunbergii, be ground into coarse powder, with 70% ethanol as solvent, dipping is seeped after 18 hours
It filters, collects liquid of just filtering, another device saves, and continues diacolation, and soluble component of waiting is filtered out completely, and liquid of filtering is added and is concentrated at 60 DEG C or less
Paste is added and is just filtered liquid, is mixed, and 70% ethyl alcohol is added to dilute, and is stood, filtration to get；
(3), prepare extract of licorice root: extracting liquorice moisturizes, and slice adds water to cook three times, 2 hours every time, collecting decoction, places 12-
Make to precipitate within 16 hours, take out supernatant until being concentrated into paste, take out in right amount, measure glycyrrhizic acid content, adjusting makes to meet rule
It is fixed, re-dry, and wear into fine powder to get；
(4), it mixes, pack: by 3-18 parts of slug extract, 1.5-9 parts of wash rice Bulbus Fritillariae Cirrhosae extract, 0.5-3 parts of mixing powder of extract of licorice root
It is broken, 20 meshes are crossed, obtain lark powder, package encapsulation, low temperature drying are at product.
4. the preparation method of a kind of slug compound preparation for preventing and treating COPD as claimed in claim 3, it is characterized in that in mixing, packet
It fills and uses following proportion in step:
6 parts of slug extract, 3 parts of wash rice Bulbus Fritillariae Cirrhosae extract, 1 part of extract of licorice root.
5. the preparation method of the slug compound preparation of a kind of prevention and treatment COPD as described in claim 3 or 4, it is characterized in that described
The product after low temperature drying is further processed into tablet, paste, spray or suppository again after mixing, packaging step.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910077918.9A CN109646562A (en) | 2019-01-28 | 2019-01-28 | A kind of slug compound preparation and preparation method thereof for preventing and treating COPD |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910077918.9A CN109646562A (en) | 2019-01-28 | 2019-01-28 | A kind of slug compound preparation and preparation method thereof for preventing and treating COPD |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109646562A true CN109646562A (en) | 2019-04-19 |
Family
ID=66121772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910077918.9A Pending CN109646562A (en) | 2019-01-28 | 2019-01-28 | A kind of slug compound preparation and preparation method thereof for preventing and treating COPD |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109646562A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200199144A1 (en) * | 2016-09-27 | 2020-06-25 | Guangxi Jiufu Biotechnology Co., Ltd | Compound and Preparation Method Thereof |
| CN114558034A (en) * | 2022-03-16 | 2022-05-31 | 中国中医科学院医学实验中心 | Extraction method of slug and application of slug in colorectal cancer resistance |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1187316A (en) * | 1997-01-08 | 1998-07-15 | 谢金魁 | 'Yubeishuangyan' plum capable of making throat comfortable and its producing method |
-
2019
- 2019-01-28 CN CN201910077918.9A patent/CN109646562A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1187316A (en) * | 1997-01-08 | 1998-07-15 | 谢金魁 | 'Yubeishuangyan' plum capable of making throat comfortable and its producing method |
Non-Patent Citations (2)
| Title |
|---|
| 严鹏科等: "蛞蝓胶囊对实验动物过敏性反应的影响", 《中国医院药学杂志》 * |
| 王永炎等: "《中医内科学》", 31 October 1999 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200199144A1 (en) * | 2016-09-27 | 2020-06-25 | Guangxi Jiufu Biotechnology Co., Ltd | Compound and Preparation Method Thereof |
| US10849934B2 (en) * | 2016-09-27 | 2020-12-01 | Guangxi Jiufu Biotechnology Co., Ltd | Compound and preparation method thereof |
| CN114558034A (en) * | 2022-03-16 | 2022-05-31 | 中国中医科学院医学实验中心 | Extraction method of slug and application of slug in colorectal cancer resistance |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2013102410A1 (en) | Oral liquid for treating allergic cough | |
| CN107648468B (en) | Traditional Chinese medicine composition for treating chronic obstructive pulmonary disease and application thereof | |
| CN109646562A (en) | A kind of slug compound preparation and preparation method thereof for preventing and treating COPD | |
| CN101041049A (en) | Chinese traditional medicine compound took orally for treating chronic bronchitis | |
| RU2519672C2 (en) | Traditional chinese medical composition for treating bronchial asthma and method for preparing it | |
| CN104940485A (en) | Traditional Chinese medicine composition for treating infantile asthma and preparation method thereof | |
| CN1272065C (en) | Medicine for treating chronic bronchitis and bronchial asthma | |
| CN1543993A (en) | Rhinitis treating medicine and its preparation | |
| WO2021103777A1 (en) | Spraying agent for preventing and treating allergic asthma combined with allergic rhinitis in children and teenagers | |
| CN1730068A (en) | Medicinal powder for treating asthma and cough | |
| CN103816410B (en) | A kind of pharmaceutical composition and application thereof for the treatment of Hospitalized Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease | |
| CN103784712A (en) | Health care product capable of repairing lung injuries caused by environmental pollution and preparation method of health care product | |
| CN110742966B (en) | Traditional Chinese medicine composition for treating chronic obstructive pulmonary disease and preparation method thereof | |
| CN115089689B (en) | Traditional Chinese medicine composition for treating spasmodic cough as well as preparation method and application thereof | |
| CN115990223B (en) | Application of composition in preparing medicine for assisting in treating chronic obstructive pulmonary disease | |
| CN116889604A (en) | Traditional Chinese medicine pill for treating allergic asthma and preparation process thereof | |
| CN1730086A (en) | Paste for treating cough and asthma and process for preparing the same | |
| CN108143944A (en) | A kind of Chinese medicine composition for treating cold | |
| CN116270557A (en) | Cough and asthma patch capable of reducing skin allergy and preparation method thereof | |
| CN1846755A (en) | Chinese medicine for treating bronchial asthma in acute attack stage and its prepn process | |
| CN102406806B (en) | Traditional Chinese medicinal powder for treating obstructive disease and embolic disease of lung and preparation method thereof | |
| CN117815324A (en) | Traditional Chinese medicine composition for treating bronchial diseases and preparation method and application thereof | |
| CN112168870A (en) | Traditional Chinese medicine cough and asthma paste and preparation method thereof | |
| CN117942372A (en) | Traditional Chinese medicine preparation for treating rhinitis and pharyngitis of respiratory system | |
| CN112691169A (en) | Medicine for treating rhinopathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190419 |